Special Issue

Leukemia

Message from the Guest Editor

Leukemia (leukaemia- British spelling) is a malignancy of the blood originating from immature leukocytes (lymphoid and myeloid). It is the most common form of childhood cancer (~1/3 of cases) and accounts for >44,000 new diagnoses and >22,000 mortalities annually in the US alone. Recent advances in both laboratory and clinic continue to improve the outcome for patients. This special edition of Cancers gives an opportunity to describe recent original research in the field of leukemia, the development or application of new platforms or insights, and/or reviews of the field. We are particularly interested in genomics, leukemia stem cell research, novel therapeutics, epidemiological studies and new biomarker studies. If you would like to discuss an idea for a paper before committing please contact the guest editor.

Guest Editor

Prof. Dr. Charles H. Lawrie

Lymphoid Malignancy Research Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK

Deadline for manuscript submissions

closed (31 July 2012)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/1602

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

